“Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps
Tapering of dupilumab to once every 12 weeks (Q12W) can be applied to super-responding patients. No clear predisposing factors were identified predicting the feasibility of extended tapering.
Authors
- Gwijde Flavius Jacobus Petrus Maria Adriaensen (ORCID: https://orcid.org/0000-0001-5498-6475)
- Linda B. L. Benoist (ORCID: https://orcid.org/0000-0002-1713-6874)
- Wytske J. Fokkens (ORCID: https://orcid.org/0000-0003-4852-229X)
- Patty E. Vonk (ORCID: https://orcid.org/0000-0002-6388-3037)
- Dinand Rienk Hoven (ORCID: https://orcid.org/0000-0001-8445-9211)
- Sietze Reitsma (ORCID: https://orcid.org/0000-0003-1734-2632)
- Rik Johannes Leonardus van der Lans (ORCID: https://orcid.org/0000-0002-5361-6752)
- Josje Otten (ORCID: https://orcid.org/0009-0003-5437-3005)
- Hester Beatrice Emilie Elzinga (ORCID: https://orcid.org/0000-0002-8576-6018)
Institutions
- Amsterdam Neuroscience (NL)
- Amsterdam University of Applied Sciences (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- Allergy
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1111/all.70151
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00